David Laxson, MD
Cardiovascular Disease · Ketchum, IDNPI 1083691398
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $133,950 of the $134,905 with a category attached, or 99.3%. Boston Scientific accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Among cardiovascular disease clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $535.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$135K
- Medtronic$164
- Chiesi USA, Inc.$12
What the payments were for
- Consulting fees$133,95099%
- Food & beverage$9431%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 249 | $134,729 |
| Medtronic | 2 | $164 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$109,350
- ELUVIA$3,450
- GENERAL CATHETERS$2,400
- GENERAL - STENTS$750
- CoreValve Evolut$144
- AVVIGO Guidance System$103
How this compares
$134,905 in reported general payments places this provider in the 95th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $216,768 |
| XareltoRivaroxaban | 40 | $40,628 |
| Repatha SureclickEvolocumab | 55 | $33,087 |
| FarxigaDapagliflozin Propanediol | 22 | $31,060 |
| EntrestoSacubitril/Valsartan | 16 | $29,465 |
| JardianceEmpagliflozin | 17 | $17,116 |
| Praluent PenAlirocumab | 21 | $14,826 |
| Flecainide Acetate | 130 | $5,179 |
| Ezetimibe | 110 | $3,167 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 90 | $2,773 |
| Metoprolol Succinate | 157 | $2,210 |
| Rosuvastatin Calcium | 138 | $1,956 |
| Atorvastatin Calcium | 152 | $1,615 |
| ClopidogrelClopidogrel Bisulfate | 77 | $868 |
| Amiodarone Hcl | 46 | $790 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Ketchum
- David HinchmanBoise$324K
- Jacob DelarosaPocatello$226K
- Ryan LongmorePocatello$60K
- Robyn BrydeBoise$27K
- Ronald FritzCoeur D Alene$17K
- Douglas BlankIdaho Falls$11K
- John ChambersIdaho Falls$8K
- Edward KimLewiston$7K
- John LassetterIdaho Falls$6K
- Peter RoanNampa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.